Latest Commercialisation News

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.

Neometals Ltd has resolved a longstanding legal dispute with a $1 million settlement, clearing the way to focus on advancing its Barrambie Gold Project and sustainable processing technologies.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

Amaero Ltd reported a remarkable 367% revenue increase to A$7.76 million for H1 FY2026, supported by a $50 million capital raise and exclusive supply agreements with industry leaders. Despite widening losses, the company is accelerating capacity expansion and securing key partnerships in aerospace and defence.

International Graphite Limited has reported pilot-scale testwork results exceeding purity targets for expandable graphite, underpinning plans for a European production facility.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

Ionic Rare Earths is advancing its rare earth magnet recycling ambitions with strategic leadership relocation, government recognition, and new funding discussions. The company’s Belfast facility gains global significance as it targets key international markets.

Rhythm Biosciences has taken a significant step toward commercialising its ColoSTAT blood test for colorectal cancer by enrolling the first physician in its Access Program, marking the transition from clinical trials to routine clinical use.

D3 Energy has secured a new Technical Cooperation Permit adjacent to its flagship helium project in South Africa, broadening its exploration footprint and reinforcing its position in the global helium market.

Everest Metals Corporation is progressing rapidly with near-term gold production at its Mt Dimer Taipan and Revere Gold projects while simultaneously developing Australia’s first rubidium industry at Mt Edon. The company reports strong resource upgrades, ongoing mining, and promising pilot plant plans for critical minerals.

Ark Mines Limited has signed a pivotal Memorandum of Understanding to trial processing of monazite ore from its Sandy Mitchell Rare Earths Project, aiming to recover critical minerals including Thorium, Neodymium, and Praseodymium.